New York, June 2, 2026, 14:07 (EDT)
Design Therapeutics shares slid on Tuesday afternoon, dropping 24 cents to $10.20 in a broader biotech selloff. The Carlsbad, California-based firm was off roughly 2.3%. The SPDR S&P Biotech ETF lost about 4.0%, and the iShares Nasdaq Biotechnology ETF slipped about 3.0%.
Design shares are in focus again since there’s been no new trial data update. The most recent post on Design’s investor page is still the May 28 Jefferies conference notice. Management is slated for a fireside chat in New York on June 4 at 1:25 p.m. EDT.
Investors are moving off the last clinical release. On May 18, Design reported four-week data from its Phase 1/2 RESTORE-FA trial, an early-stage safety and efficacy study, with dose-dependent gains in Friedreich ataxia. The rare disorder is inherited. The company’s drug DT-216P2 is designed to increase frataxin levels by targeting the faulty gene behind the disease.
Design Therapeutics CEO Pratik Shah said the data showed “endogenous frataxin” rose and patients saw clinical gains after four weeks. The company said 16 patients finished treatment, with no serious side effects or dropouts. Design plans a registrational path, aiming for studies or data to back regulatory approval. Design Therapeutics, Inc
Wall Street viewed the May data as encouraging but not conclusive. RBC Capital lifted its price target on Design to $20 from $14 and maintained an Outperform rating, saying early efficacy data were promising. But the broker also pointed out the trial had a small sample size, limited follow-up, and questions around the dose correlation.
Leerink Partners analyst Joseph Schwartz told Investor’s Business Daily the results were “further validation of the company’s GeneTAC platform,” pointing to the promise of Design’s gene-targeted small-molecule approach. But despite that bull case, the stock gave up an early rally after the May 18 data and ended down sharply, the same report said. Investors
Competition is showing up early. Biogen sells Skyclarys, or omaveloxolone, which its patient website calls the first and only FDA-approved prescription drug for Friedreich ataxia in people 16 and up. Larimar Therapeutics, also in the Friedreich ataxia space, said in February it got FDA breakthrough therapy status for nomlabofusp. Larimar repeated plans for a biologics license application in June 2026.
Peer activity didn’t help much Tuesday. Biogen slipped around 2.0% in the afternoon session. Larimar dropped roughly 5.1%, which kept pressure on the sector, although Design’s decline wasn’t as steep as in some other small rare-disease stocks.
Design said last month it held $222.8 million in cash, equivalents and investment securities at March 31. That should fund its planned work into 2029, according to the company. Design booked a first-quarter net loss of $17.6 million.
But the risk is clear. The RESTORE-FA data is from an early readout with a small number of patients, and bigger or longer trials might not give the same results. Design’s 10-Q also said the company isn’t cash flow positive from its operations, expects to keep losing money, and could need more funding for research, clinical work or any future commercial projects if its products get approved.
DSGN trades more like a preclinical story than a commercial biotech at this point. Investors are watching to see if management brings enough new details at Jefferies to settle a share price that’s been sliding since the May clinical update. Smaller biotechs aren’t getting the benefit of the doubt in this market.
